woodbinetrust.com
Woodbine Trust Company - Industry Links
http://www.woodbinetrust.com/industry/index.html
Woodbine Trust Company would like to share with you the following sites that provide the various resources to the securities industry. We hope you will find them useful and we take no credit or responsibility for the content of the sites. FP Infomart - research tool. International Financial Centre B.C. Registrar of Companies in B.C. Wwwfin.gov.bc.ca. Canadian National Stock Exchange. Government of British Columbia. Government of New Brunswick. Government of Nova Scotia. Government of Prince Edward Island.
biotuesdays.com
Response Biomedical promotes COO Kinnaird to CEO | BioTuesdays
http://biotuesdays.com/2015/05/20/response-biomedical-promotes-coo-kinnaird-to-ceo
Sunday, August 21, 2016. You are here: Home. Response Biomedical promotes COO Kinnaird to CEO. Response Biomedical promotes COO Kinnaird to CEO. May 20, 2015. Middot; Leave a Comment. Response Biomedical (OTCBB:RPBIF; TSX:RBM) has promoted COO, Dr. Barbara Kinnaird, to the position of CEO, effective immediately, succeeding interim CEO, Dr. Anthony Holler. Barbara Kinnaird, Ph.D. Middot; Tagged with Dr. Anthony Holler. Subscribe to BioTuesdays Weekly Email. WB starts 4 chronic Hep B biotechs at outperform.
biotuesdays.com
BioTuesdays Publishing Corporation | BioTuesdays
http://biotuesdays.com/about-us
Sunday, August 21, 2016. You are here: Home. One thing is crystal clear for the past couple of years, there has been a noticeable void of traditional business media coverage of all but the very largest healthcare companies. So, we’ve created. To change that. Our goal is to give great, but not necessarily big or well known, healthcare companies and their stories the exposure that they deserve. Follow us on Twitter at http:/ twitter.com/biotuesday. Subscribe to BioTuesdays Weekly Email.
biotuesdays.com
Axcelon leverages bacterial cellulose expertise with Nanoderm launch | BioTuesdays
http://biotuesdays.com/2015/05/05/axcelon-leverages-bacterial-cellulose-expertise-with-nanoderm-launch
Sunday, August 21, 2016. You are here: Home. Axcelon leverages bacterial cellulose expertise with Nanoderm launch. Axcelon leverages bacterial cellulose expertise with Nanoderm launch. May 5, 2015. Middot; Leave a Comment. Axcelon Biopolymers, which plans to go public in the current quarter, has developed a sales and marketing plan with a leading wholesaler and its own sales team to gain maximum market share in Canada for its Nanoderm bacterial cellulose dressing to heal burns and wounds. The company’s l...
biotuesdays.com
T2 Biosystems to double sales force this year | BioTuesdays
http://biotuesdays.com/2015/05/12/t2-biosystems-to-double-sales-force-this-year
Sunday, August 21, 2016. You are here: Home. T2 Biosystems to double sales force this year. T2 Biosystems to double sales force this year. May 12, 2015. Middot; Leave a Comment. T2 Biosystems (NASDAQ:TTOO), which entered 2015 with seven direct sales reps, plans to add another eight during the year as it continues to roll out its first products: the T2Candida panel and T2Dx instrument for the detection of. Fungal infections that cause sepsis. As a serious threat due to antifungal drug resistance. The test...
biotuesdays.com
Briefs | BioTuesdays
http://biotuesdays.com/category/briefs
Sunday, August 21, 2016. You are here: Home. WB starts 4 chronic Hep B biotechs at outperform. August 19, 2016. Middot; Leave a Comment. Middot; Tagged with ABUS. Leerink downgrades Mirna to market perform. August 17, 2016. Middot; Leave a Comment. Middot; Tagged with clinical development. WB drops coverage of OncoGenex. August 16, 2016. Middot; Leave a Comment. Tweet William Blair dropped coverage of OncoGenex (NASDAQ:OGXI) after the company announced that the AFFINITY study did not meet the primary end...
biotuesdays.com
HCW starts StemCells at buy | BioTuesdays
http://biotuesdays.com/2015/05/18/hcw-starts-stemcells-at-buy
Sunday, August 21, 2016. You are here: Home. HCW starts StemCells at buy. HCW starts StemCells at buy. May 18, 2015. Middot; Leave a Comment. HC Wainwright has launched coverage of StemCells (NASDAQ:STEM) with a buy rating and using a discounted cash flow analysis to derive a price target of $1. The stock closed at 62 cents on Friday. In a small Phase 1/2 trial, the company demonstrated safety and positive interim results from its cohort 1 group of four patients. Specifically, the rate of geographic ...
biotuesdays.com
Tuesday Features | BioTuesdays
http://biotuesdays.com/category/tuesday-features
Sunday, August 21, 2016. You are here: Home. In conversation with Ben Haynor. August 16, 2016. Middot; Leave a Comment. Tweet As a senior research analyst with Feltl and Co. for the past six years, Ben Haynor ranked second in the May 2013 Wall Street Journal Best on the Street publication in the Medical Equipment and Supplies category and was named the top stock picker in U.S. Health Care Equipment and Supplies in StarMine’s 2013 […]. Filed under Tuesday Features. Middot; Tagged with agriculture. Tweet C...
biotuesdays.com
GeneNews in pact to increase stake in IDL venture | BioTuesdays
http://biotuesdays.com/2015/05/19/genenews-in-pact-to-increase-stake-in-idl-venture
Sunday, August 21, 2016. You are here: Home. GeneNews in pact to increase stake in IDL venture. GeneNews in pact to increase stake in IDL venture. May 19, 2015. Middot; Leave a Comment. GeneNews (TSX:GEN) has entered into a purchase agreement with Cobalt Healthcare Consultants to purchase Health Diagnostic Laboratory’s (HDL) one-third ownership stake in their Innovative Diagnostic Laboratory (IDL) joint venture for $4-million. In fact, it is our intent to increase our ownership even beyond what was achie...
biotuesdays.com
Archives | BioTuesdays
http://biotuesdays.com/archive-page
Sunday, August 21, 2016. You are here: Home. WB starts 4 chronic Hep B biotechs at outperform. Leerink downgrades Mirna to market perform. WB drops coverage of OncoGenex. In conversation with Ben Haynor. Profound Medical names Arun Menawat as CEO. Leerink reiterates rating on Aurinia following trial results. Vital Therapies names Faheem Hasnain as a director. Microbix sees record sales in fiscal 2016. Roth ups CymaBay price target to $6. Maxim cuts Bio-Path price target to $2. Cellect completes NASDAQ IPO.
SOCIAL ENGAGEMENT